Hemab Therapeutics Holdings, Inc. (COAG) earnings
Only 2 fiscal years of net income are on record here for Hemab Therapeutics Holdings, Inc. (COAG); a history needs at least 3. Figures as of 18 Nov 2026, 10:38 UTC, from Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- -$63.91M
- Fiscal years on record
- 22024–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Not enough data
A history of net income needs at least 3 fiscal years; 2 are on record here for Hemab Therapeutics Holdings, Inc.. Nothing is estimated to fill the gap. What is on record is in the table below.
Hemab Therapeutics Holdings, Inc. earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | -$63.91M | — | |
| 2024 | -$48.71M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Hemab Therapeutics Holdings, Inc., figure by figure
- Hemab Therapeutics Holdings, Inc. market cap
- Hemab Therapeutics Holdings, Inc. revenue
- Hemab Therapeutics Holdings, Inc. earnings per share (EPS)
- Hemab Therapeutics Holdings, Inc. P/E ratio
- Hemab Therapeutics Holdings, Inc. P/S ratio
- Hemab Therapeutics Holdings, Inc. P/B ratio
- Hemab Therapeutics Holdings, Inc. free cash flow
- Hemab Therapeutics Holdings, Inc. operating margin
- Hemab Therapeutics Holdings, Inc. dividend
- Hemab Therapeutics Holdings, Inc. shares outstanding
- Hemab Therapeutics Holdings, Inc. total debt
- Hemab Therapeutics Holdings, Inc. cash on hand
- Hemab Therapeutics Holdings, Inc. total assets
- Hemab Therapeutics Holdings, Inc. return on equity (ROE)
- Hemab Therapeutics Holdings, Inc. return on invested capital (ROIC)
Hemab Therapeutics Holdings, Inc. (COAG) overview: price, valuation and scorecard
Hemab Therapeutics Holdings, Inc. earnings: questions and answers
How is Hemab Therapeutics Holdings, Inc.'s net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement. For Hemab Therapeutics Holdings, Inc. it is on record here for 2 fiscal years, 2024 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Hemab Therapeutics Holdings, Inc. (COAG) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/COAG/earnings
Underlying data: Yahoo Finance.